Pharmaceutical

FibroBiologics and Charles River link for chronic disease therapies manufacture

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.

Oct 22, 2024 - 04:00
FibroBiologics and Charles River link for chronic disease therapies manufacture
FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.
Read the original article

Tags:

Previous Article

ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology

Next Article

FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

After FDA nod, Better Therapeutics races to boost dwindling cash

After FDA nod, Better Therapeutics races to boost dwind...

Jul 14, 2023

Interview: Dr Alan S Louie – US Food and Drug Administration Delays

Interview: Dr Alan S Louie – US Food and Drug Administr...

Apr 16, 2023

Rusan Pharma’s API Plant in Ankleshwar Receives USFDA GMP Approval

Rusan Pharma’s API Plant in Ankleshwar Receives USFDA G...

Jul 22, 2024